Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Top five tips for easy breathing during holiday season

Getting out the boxes of holiday decorations from years gone by is a time-honored tradition. But in addition to stirring up memories, it also stirs up allergies. "The dust from the boxes and on the decorations that have been packed away in dank basements or dusty attics is triggering reactions in my allergy and asthma patients," said Joseph Leija, MD, allergist at Gottlieb Memorial Hospital.

14 Dec 2011

Statins linked with reduced risk of death among hospitalized flu patients

The two main ways to prevent and control influenza today are annual immunization and antiviral drugs. A team of investigators has found that statins, cholesterol-lowering drugs, may offer an additional treatment to complement these approaches and reduce mortality among patients hospitalized with influenza.

14 Dec 2011

Mandatory vaccination policy increases healthcare worker flu vaccination rates

A California hospital raised its employee influenza vaccination rate above 90 percent by shifting from a voluntary vaccination program to one mandating all healthcare workers either get vaccinated or wear a mask at work for the entire flu season (December through March).

13 Dec 2011

Research describes advantages of new vaccine adjuvant

New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest it could be useful for enhancing protection against a number of different infections.

13 Dec 2011

Book on hot health topics

The intersection of health care, politics and policy is a controversial one. A new book of lively essays takes on all of today's hot health topics: alternative medicine, swine flu, health care reform, screening mammograms, taxes to decrease soda consumption, gun control and many more.

13 Dec 2011

Study describes new method that synthesizes novel anti-HIV protein

The most abundant and important molecules in all living organisms are proteins; after all they manage to participate in every single one of life's essential reactions. So it is easy to see why scientists have been making such a fuss trying to learn how to synthesise them in laboratory as this would provide them with a tool of extraordinary potential. Unfortunately, this has not proved easy.

13 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Parents blame swine flu vaccine for son’s narcolepsy

A six year old boy’s parents have claimed that he developed narcolepsy after a swine flu vaccination. Caroline Hadfield said son Josh lost muscle control and started sleeping up to 19 hours a day three weeks after being given Pandemrix nearly two years ago.

12 Dec 2011

WTC disaster results in increased risk of physical and mental health conditions after 9/11

The World Trade Center disaster exposed nearly half a million people to hazardous chemicals, environmental toxins, and traumatic events. According to research published in the December 2011 issue of Elsevier-published journal Preventive Medicine, this has resulted in increased risk of developing physical and mental health conditions after 9/11.

12 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.

12 Dec 2011

Celgene announces results from azacitidine Phase 1 study on AML

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced results from a multi-center Phase I study that explored multiple dosing schedules of oral azacitidine in 23 patients with acute myeloid leukemia (AML), myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML) who were not candidates for other therapies or who had failed previous regimens.

12 Dec 2011

Prevention practices for catheter-associated urinary tract infections lacking in most hospitals

Hospitals are working harder than ever to prevent hospital-acquired infections, but a nationwide survey shows few are aggressively combating the most common one - catheter-associated urinary tract infections.

9 Dec 2011

New international consortium aims to prepare researchers for next pandemic

"A group of health organizations [on Wednesday] launched a new international consortium to better prepare the clinical research community to respond to the next pandemic or other emerging health threat," CIDRAP News reports (Schnirring, 12/7).

9 Dec 2011

Experimental sublingual vaccine shows promise against influenza infection

Scientists from the International Vaccine Institute (IVI) have discovered that an antigen common to most influenza viruses, and commonly referred to as matrix protein 2 (M2), when administered under the tongue could protect mice against experimental infection caused by various influenza viruses, including the highly pathogenic avian H5 virus and the pandemic H1 ("swine flu") virus.

9 Dec 2011

Paper calls for strong steps to control global crisis of antibiotic-resistant infections

Shahriar Mobashery, a University of Notre Dame researcher, is one of the coauthors of a new paper by a group of the world's leading scientists in academia and industry that calls for strong steps to be taken to control the global crisis of antibiotic resistance in bacteria. The group issued a priority list of steps that need to be taken on a global scale to resolve the crisis.

9 Dec 2011

Nighttime-lights imagery can pinpoint disease hotspots

Normally used to spot where people live, satellite images of nighttime lights can help keep tabs on the diseases festering among them, too, according to new research.

9 Dec 2011

New gene editing technique can heal sickle cell patients with their own cells

Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin.

8 Dec 2011

Massive and consistent changes in inflammatory gene expression seen in trauma, burns

Serious traumatic injuries, including major burns, set off a "genomic storm" in human immune cells, altering around 80 percent of the cells' normal gene expression patterns. In a report to appear in the December Journal of Experimental Medicine, members of a nationwide research collaborative describe the initial results of their investigation into the immune system response to serious injury, findings which have overturned some longstanding assumptions.

8 Dec 2011

Inviragen presents DENVax Phase 1 trial results on dengue at ASTMH annual meeting

Inviragen, Inc. presented results of the Phase 1 clinical trial of DENVax conducted in Colombia at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting today.

8 Dec 2011